Key result
Prior COVID-19 infection is linked to ~29% higher post-CABG cholesterol levels.
Why the study?
It was unknown whether a history of COVID-19 causes alterations in the clinical and laboratory status of patients undergoing CABG.
Does a history of COVID-19 infection alter the clinical and laboratory status of patients who have undergone CABG?
Observational (n=42)
No
Does a history of COVID-19 infection alter the clinical and laboratory status of patients who have undergone CABG?
Patients with a history of COVID-19 who underwent CABG exhibit worse lipid profiles and a higher prevalence of chronic kidney disease compared to those without prior COVID-19.
Prior COVID-19 associated with higher post-CABG cholesterol; leaves open whether this warrants adjusted lipid management or affects outcomes.
Aim . To evaluate whether the history of coronavirus disease 2019 (COVID-19) in patients undergone cardiac surgery (coronary artery bypass grafting - CABG) causes alterations in their clinical and laboratory status. Materials and methods . Clinical data of 42 patients undergone CABG in 2019 were analyzed. Informed written consent was obtained from all participants in accordance with the Declaration of Helsinki. Determination of COVID-19 positive or negative status was performed due to results of nasal and throat swabs using reverse transcriptase-polymerase chain reaction (RT-PCR) or positive serum COVID-19 antibodies. Statistical analyses were performed using Jamovi software. Results . In COVID-19 positive patients compared to COVID-19 negative patients: the level of serum cholesterol was significantly higher: 5,22 [4,03; 6,22] vs. 4.06 [3,56; 4,88] mmol/L, р = 0,005; OR 0,492 [0,282; 0,858] 95% CI, p ratio 0,012; the level of low-density lipoproteins was significantly higher: 3,27 [2,16; 3,96] vs. 2,28 [1,60; 3,08] mmol/L, p 0,014; OR 0,518 [0,294; 0,914] 95% CI, p ratio 0,023; the incidence of chronic kidney disease stage C3a (CKD) was higher: 7 (16,7%) vs. 1 (2,4%), p 0,008; OR 0,0779 [0,00855; 0,710] 95% CI, p ratio 0,024; tendency to a higher serum creatinine: 89,7 [83,0; 105,0] vs. 81,0 [75,0; 90,5] μmol/L, p 0,060; OR 0,976 [0,945; 1,01] 95% CI, p ratio 0,153; tendency to a lower glomerular filtration rate using CKD-EPI: 66,1 ± 17,3 vs. 75,7 ± 16,1 ml/min/1,73m 2 , p 0,034; OR 1,0368 [0,9962; 1,08] 95% CI, p ratio 0,076; tendency to a higher serum D-dimer level: 154 [104; 364] vs. 137 [97; 173] ng/ml, p 0,07; OR 0,997 [0,994; 1,0] 95% CI, p ratio 0,141; tendency to a higher mean heart rate 75 [71; 79,5] vs. 72 [63; 74,5] bpm, p 0,026; PR 0,951 [0,886; 1,02] 95% CI, p ratio 0,169. Heart rate variability parameters haven’t shown statistical significance between groups. Conclusion . Patients with a history of COVID-19 who underwent CABG had alterations in their clinical and laboratory status. These alterations should be thoroughly investigated to make a forehanded change in their therapy.
No takes yet. Share an insight, caveat, or question.
Логинова et al. (2023) conducted an observational in Ischemic heart disease post-CABG (n=42). History of COVID-19 vs. No history of COVID-19 was evaluated on Serum cholesterol level (mmol/L) (OR 0.492, 95% CI 0.282-0.858, p=0.005). Patients with a history of COVID-19 who underwent CABG had significantly higher serum cholesterol levels (5.22 vs 4.06 mmol/L) compared to those without a history of COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: